Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022011065 - TUMOR-ACTIVATED ALLOREACTIVE AND XENOREACTIVE T CELLS AND THEIR USE IN IMMUNOTHERAPY AGAINST CANCER

Publication Number WO/2022/011065
Publication Date 13.01.2022
International Application No. PCT/US2021/040765
International Filing Date 07.07.2021
IPC
C12N 5/0783 2010.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
A61K 35/17 2015.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
CPC
A61K 2039/5156
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
515Animal cells
5156expressing foreign proteins
A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 39/001106
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
0005Vertebrate antigens
0011Cancer antigens
001102Receptors, cell surface antigens or cell surface determinants
001103Receptors for growth factors
001106Her-2/neu/ErbB2, Her-3/ErbB3, Her 4/ErbB4
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/7051
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70503Immunoglobulin superfamily
7051T-cell receptor (TcR)-CD3 complex
C07K 16/2809
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
2809against the T-cell receptor (TcR)-CD3 complex
Applicants
  • THE NEMOURS FOUNDATION [US]/[US]
Inventors
  • MA, Zhengyu
Agents
  • LOEB, Bronwen M.
  • MEYER, Mercedes K.
  • FENG, Zhengyu
  • BRUENJES, Christopher P.
Priority Data
63/048,88107.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) TUMOR-ACTIVATED ALLOREACTIVE AND XENOREACTIVE T CELLS AND THEIR USE IN IMMUNOTHERAPY AGAINST CANCER
(FR) LYMPHOCYTES T ALLORÉACTIFS ET XÉNORÉACTIFS ACTIVÉS PAR UNE TUMEUR ET LEUR UTILISATION EN IMMUNOTHÉRAPIE CONTRE LE CANCER
Abstract
(EN) Provided are tumor-activated alloreactive or xenoreactive T cells that are active only at the tumor sites and methods for the generation of tumor-activated alloreactive or xenoreactive T cells. Also provided are methods for using these tumor-activated alloreactive or xenoreactive T cells to treat tumors and cancers. The alloreactivity or xenoreactivity of the T cells at the tumor sites leads to the killing of tumor cells and stromal cells that express mismatched HLA molecules. The lack of activity of these T cells at non-tumor locations prevents attack on normal tissues. Further related methods and products are provided.
(FR) L'invention concerne des lymphocytes T alloréactifs ou xénoréactifs activés par une tumeur qui sont actifs uniquement au niveau des sites tumoraux, ainsi que des procédés pour la génération de lymphocytes T alloréactifs ou xénoréactifs activés par une tumeur. L'invention concerne également des procédés d'utilisation de ces lymphocytes T alloréactifs ou xénoréactifs activés par une tumeur pour traiter des tumeurs et des cancers. L'alloréactivité ou la xénoréactivité des lymphocytes T au niveau des sites tumoraux conduit à la destruction de cellules tumorales et de cellules stromales qui expriment des molécules d'antigène leucocytaire humain mesappariées. Le manque d'activité de ces lymphocytes T au niveau d'emplacements non tumoraux empêche une attaque sur des tissus normaux. L'invention concerne également d'autres procédés et systèmes associés.
Latest bibliographic data on file with the International Bureau